| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_777a7d4b6d214f486f77cccc5afc193d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24222
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-186 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-576
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-576 |
| filingDate |
2020-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ac7d315dac60bf89e567762388d9d3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a97290a5f9aa782b312ec3706a992b0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d99b892a330c96246a0be3315be7f7a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01750f94cc5da30469776082b7607032
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b72469e6ad93fa9b52cbf4ca8522f389
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a83b9fac27630c03f4a3e428a73eb5f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40b92589dfac96c11ada7c58c87f68c9 |
| publicationDate |
2020-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020369727-A1 |
| titleOfInvention |
Composition and method for treating a patient having liver cirrhosis |
| abstract |
Peptide inhibitors of activation of hepatitis C virus (HCV) NS3 protease are disclosed. They are analogs of the activation peptide HCV NS4 of residues 21-33 of SEQ ID NO: 2 and contain non-proteinogenic amino acids. Competitive binding studies showed the peptide analogs bind HCV NS3 protease at the activation site. |
| priorityDate |
2019-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |